デフォルト表紙
市場調査レポート
商品コード
1005799

内分泌検査の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)

Endocrine Testing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 132 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
内分泌検査の世界市場:成長、動向、COVID-19の影響、予測(2021年~2026年)
出版日: 2021年05月13日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 132 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

内分泌検査の市場規模は、2020年に91億7,062万米ドルとなり、2021年~2026年の予測期間中に6.15%のCAGRで成長し、2026年までに131億1,951万米ドルとなると予想されています。

パンデミックの間、甲状腺疾患を持つ人々はCOVID‐19に感染しやすいことが多くの調査研究によって示されているため、甲状腺ホルモンのレベルをチェックおよび管理するために、世界中でさまざまな内分泌検査が大幅に必要とされています。2021年1月の調査研究「COVID-19患者50人の甲状腺機能分析:レトロスペクティブスタディ」によると、この研究結果は、COVID-19が深刻であるほど、TSHおよびTT3レベルが低下することを、統計的有意性をもって示しました。TSHおよびTT3レベルの低下の程度は、疾患の重症度と正の相関関係がありました。したがって、血清TSHおよびTT3レベルの変化は、COVID-19の経過の重要な兆候です。

内分泌障害の蔓延と診断技術の進歩は、主に市場の成長を牽引しています。さらに、世界中の早期診断と治療に関する意識の高まりと相まって、高齢化人口の増加は、市場の成長を後押しすると予想されます。内分泌検査は、内分泌腺から分泌されるホルモンのレベルを測定し、肥満、糖尿病、甲状腺疾患などのさまざまな病気の診断を指します。2019年の国際連合によると、糖尿病の成人は約4億6,300万人で、2045年までには7億人に増加すると予測されています。

世界保健機関によると、肥満の有病率は1975年のレベルに比べて2016年に3倍になりました。18歳以上の約19億人の成人が太りすぎでした。これらのうち、約6億5,000万人が肥満でした。これらの数字は、成人の39%と13%が太りすぎと肥満であることに、大まかに換算されます。2019年には、5歳未満の約3,800万人の子供が太りすぎまたは肥満でした。さらに、アルコール摂取は、さまざまな内分泌疾患や障害の最大のリスク要因の1つです。世界的に見て、先進地域の高所得国はアルコール消費量が最も多い国です。この大量のアルコール摂取も、病気の負担の大きな要因の1つとなっています。内分泌検査ツールの需要が大きいため、市場のプレーヤーは製品開発と新しい発売にも焦点を当てています。例えば。2018年10月、DRG Diagnosticsは、ヒト血清中の遊離サイロキシンの直接定量を目的としたFree T4 ELISA検査キットを発売しました。

世界中の多くの国での糖尿病、甲状腺障害の有病率の高まりは、市場の成長をさらに加速させると予想されます。ただし、検査技術の開発コストが高いため、予測期間中の市場の成長が妨げられると予想されます。

当レポートでは内分泌検査の世界市場を調査し、市場の概要、市場の成長要因および阻害要因の分析、市場機会、COVID-19の影響、検査・テクノロジー・エンドユーザー・地域別の市場規模の推移と予測、競合情勢、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進要因
    • 内分泌疾患の有病率の増加と高齢者人口の増加
    • 製品技術の進歩
  • 市場の抑制要因
    • 高コストの高度な内分泌検査装置
    • 後進国および新興諸国認識の欠如
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 検査別
    • 甲状腺検査
    • インスリン検査
    • ヒト絨毛膜ゴナドトロピン試験
    • プロラクチン検査
    • 黄体形成ホルモン検査
    • プロゲステロンテスト
    • その他
  • テクノロジー別
    • イムノアッセイ
    • タンデム質量分析
    • センサー技術
    • その他
  • エンドユーザー別
    • 病院
    • 臨床検査室
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東とアフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • AB Sciex
    • Abbott Laboratories
    • Agilent Technologies, Inc.
    • Biomedical Technologies
    • bioMerieux SA
    • Bio-Rad Laboratories, Inc.
    • Danaher Corporation
    • DiaSorin SpA
    • F. Hoffmann-La Roche Ltd
    • Hologic Inc.
    • Ortho Clinical Diagnostics
    • Qiagen NV
    • Quest Diagnostics
    • Siemens Healthineers AG
    • Thermo Fisher Scientific

第7章 市場機会と動向

目次
Product Code: 68123

The endocrine testing market was valued at USD 9,170.62 million in 2020 and is expected to reach USD 13,119.51 million by 2026, registering a CAGR of 6.15% during the forecast period.

During the Pandemic, many research studies have been demonstrated that people with thyroid disorders are more prone to the COVID 19 infection, thus creating a significant demand for various endocrine tests globally in order to check and manage the thyroid hormone levels. As per the January 2021 research study titled "Thyroid Function Analysis in 50 Patients with COVID-19: A Retrospective Study" , the results of the study demonstrated that the more severe the COVID-19, the lower the TSH and TT3 levels were, with statistical significance. The degree of the decreases in TSH and TT3 levels was positively correlated with the severity of the disease. Hence, the changes in serum TSH and TT3 levels are the important manifestations of the courses of COVID-19.

The growing prevalence of endocrine disorders and advancements in diagnostic technologies are primarily driving the market growth. Furthermore, the growing older population coupled with rising awareness about early diagnosis and treatment around the world is anticipated to boost the market growth. Endocrine testing refers to the measuring of levels of hormones secreted by the endocrine glands and diagnosis of various disorders such as obesity, diabetes, thyroid disease, and others. According to the International Federation in 2019, Diabetes approximately 463 million adults were living with diabetes and by 2045 it will rise to 700 million.

According to the World Health Organization, the prevalence of obesity had tripled in 2016, compared to the levels in 1975. About 1.9 billion adults, aged 18 years or above, were overweight. Of these, about 650 million were obese. These numbers roughly translate to 39% and 13% of the adults as overweight and obese, respectively. About 38 million children under the age of five were overweight or obese in 2019. In addition, alcohol consumption is one of the largest risk factors for various endocrine diseases and disabilities. Globally, high-income countries of the developed region have the highest alcohol consumption. This high consumption of alcohol is also serving as one of the major factors for the burden of the disease. Owing to the large demand for endocrine testing tools the market players are also focusing on product development and novel launches. For instance. in October 2018, DRG Diagnostics launched Free T4 ELISA test kits, The Free T4 ELISA Assay Kit is intended for the direct quantitative determination of free thyroxine in human serum.

The growing prevalence of diabetes, thyroid disorders in many of the countries around the globe is anticipated to further fuel the market growth. However, the high cost for the development of testing technologies is expected to impede market growth over the forecast period.

Key Market Trends

Thyroid Stimulating Hormone Testing (TSH) Anticipated to have Lucrative Growth

Thyroid-stimulating hormone (TSH) is produced by the pituitary gland and stimulates the thyroid gland to produce thyroxine and triiodothyronine which helps in metabolism. TSH testing used to measure thyroid level. The burden of thyroid disorders is increasing across the globe. For instance, as per the American Thyroid Association (ATA), an estimated 20 million Americans have some form of thyroid disease in 2019. It was estimated that more than 12 % of the U.S. population is anticipated to develop a thyroid condition during their lifetime. The major risk factors for thyroid-associated disorders are smoking, alcohol, and tobacco consumption. As per November 2019 study conducted by researchers from the Department of Nephrology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands, the results of the study demonstrated that Cigarette smoking is associated with a moderately higher level of FT4 and FT3, and lower TSH levels, which suggest partly opposing effects of alcohol consumption.

TSH measurement has recently gained a lot of importance in thyroid function testing mainly due to the technological developments in these tests facilitating cost-effective disease screening. TSH has also introduced new definitions of subclinical hypothyroidism or hyperthyroidism, along with delivering biochemical treatment targets. Furthermore, advancements in product technologies coupled with the growing affordability for healthcare is fueling the market growth. Mass spectroscopy is now used along with liquid chromatography for accurate results. This is believed to fuel market growth over the forecast period.

North America is Anticipated to Have Significant Share

North America is anticipated to have a significant share owing to the factors such as well-established healthcare infrastructure, high prevalence of obesity, advancements in diagnostic technologies, and new product launches. The less physical activity and growing prevalence of thyroid disorders are anticipated to fuel the market growth.

According to Health and Human Services (HHS), only less than 5% of adults participate in the 30 minutes of physical activity each day in the United States. More than 80% of adults do not meet the required guidelines for muscle strengthening and aerobic activities. This is leading to the consequences such as an imbalance of hormones due to obesity and diseases or conditions associated with the thyroid which is augmenting the demand for thyroid testing services. According to the American Cancer Society, it was estimated that about 44,280 new cases of thyroid cancer (12,150 in men and 32,130 in women) and about 2,200 deaths from thyroid cancer (1,050 men and 1,150 women) will be reported in the United States in 2021.

North America is likely to witness major growth in the coming years, owing to several initiatives, such as compulsory screening of newborns for congenital hypothyroidism, revolutionary research work on thyroid hormone function, cost-effective methods to detect thyroid cancer, promising research on Graves' disease, which is likely to further lead to improved prognosis, and new preventive treatments of thyroid diseases.

In mexico the growth is attributed to the rising prevalence of the disorders coupled with innovative product launches. For instance, in 2018, MedTech pioneer Proteomics International Laboratories Ltd launched of its world leading predictive diagnostic test for diabetic kidney disease, "PromarkerD" in Mexican Market. Hence, owing to the above-mentioned factors, the market studied is believed to grow over the forecast period in this region.

Competitive Landscape

Global endocrine testing market is moderately competitive and there are several local as well as international companies in this market. Market players are focusing on new product launches, product innovations and geographical expansion. The key market players operating in the market include Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., bioMerieux SA, F. Hoffmann-La Roche Ltd and Siemens AG among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Endocrine Disorders and Increasing Geriatric Population
    • 4.2.2 Advancements in Product Technologies
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Advanced Endocrine Testing Devices
    • 4.3.2 Lack of Awareness in Underdeveloped and Developing Countries
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test
    • 5.1.1 Thyroid Test
    • 5.1.2 Insulin Test
    • 5.1.3 Human Chorionic Gonadotropin Test
    • 5.1.4 Prolactin Test
    • 5.1.5 Luteinizing Hormone Test
    • 5.1.6 Progesterone Test
    • 5.1.7 Others
  • 5.2 By Technology
    • 5.2.1 Immunoassay
    • 5.2.2 Tandem Mass Spectroscopy
    • 5.2.3 Sensor Technology
    • 5.2.4 Others
  • 5.3 By End-User
    • 5.3.1 Hospitals
    • 5.3.2 Clincal Laboratories
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AB Sciex
    • 6.1.2 Abbott Laboratories
    • 6.1.3 Agilent Technologies, Inc.
    • 6.1.4 Biomedical Technologies
    • 6.1.5 bioMerieux SA
    • 6.1.6 Bio-Rad Laboratories, Inc.
    • 6.1.7 Danaher Corporation
    • 6.1.8 DiaSorin S.p.A.
    • 6.1.9 F. Hoffmann-La Roche Ltd
    • 6.1.10 Hologic Inc.
    • 6.1.11 Ortho Clinical Diagnostics
    • 6.1.12 Qiagen N.V.
    • 6.1.13 Quest Diagnostics
    • 6.1.14 Siemens Healthineers AG
    • 6.1.15 Thermo Fisher Scientific

7 MARKET OPPORTUNITIES AND FUTURE TRENDS